Nootropic Activity of a Novel (-)-Cytisine Derivative (3aR,4S,8S,12R, 12aS,12bR)-10-Methyl-2-Phenyloctahydro-1H-4,12a-Etheno-8,12-Methanopyrrolo[3’,4’:3,4]Pyrido[1,2-a] [1,5]Diazocine-1,3,5(4H)-Trione
- Autores: Makara N.S.1, Sapozhnikova T.A.1, Khisamutdinova R.Y.1, Tsypysheva I.P.1, Borisevich S.S.1, Kovalskaya A.V.1, Petrova P.R.1, Khursan CL.1, Zarudii F.S.1,2
- 
							Afiliações: 
							- Laboratory of Bioorganic Chemistry and Catalysis, Ufa Institute of Chemistry, Russian Academy of Sciences
- Department of Pharmacology No. 1, Bashkir State Medical University, Ministry of Health of the Russian Federation
 
- Edição: Volume 164, Nº 4 (2018)
- Páginas: 434-438
- Seção: Pharmacology and Toxicology
- URL: https://journals.rcsi.science/0007-4888/article/view/239670
- DOI: https://doi.org/10.1007/s10517-018-4006-0
- ID: 239670
Citar
Resumo
We performed screening of nootropic properties of 10 new derivatives of quinolizidine alkaloid (-)-cytisine. Compounds with β-endo stereochemistry were more active than α-endo-isomers. Under stress conditions (3aR,4S,8S,12R,12aS,12bR)-10-methyl-2-phenyloctahydro-1H-4,12a-etheno-8,12-methanopyrrolo[3’,4’:3,4]pyrido[1,2-a] [1,5]diazocine-1,3,5(4H)-trione enhanced memory and had a positive effect on cognitive functions of rats. According to molecular docking data, the nootropic activity of the compound can be associated with its affinity for the glutamate-binding subunits GluK1 and GluR2 of the kainate and AMPA receptor, respectively.
Sobre autores
N. Makara
Laboratory of Bioorganic Chemistry and Catalysis, Ufa Institute of Chemistry, Russian Academy of Sciences
							Autor responsável pela correspondência
							Email: newpharm@anrb.ru
				                					                																			                												                	Rússia, 							Ufa						
T. Sapozhnikova
Laboratory of Bioorganic Chemistry and Catalysis, Ufa Institute of Chemistry, Russian Academy of Sciences
														Email: newpharm@anrb.ru
				                					                																			                												                	Rússia, 							Ufa						
R. Khisamutdinova
Laboratory of Bioorganic Chemistry and Catalysis, Ufa Institute of Chemistry, Russian Academy of Sciences
														Email: newpharm@anrb.ru
				                					                																			                												                	Rússia, 							Ufa						
I. Tsypysheva
Laboratory of Bioorganic Chemistry and Catalysis, Ufa Institute of Chemistry, Russian Academy of Sciences
														Email: newpharm@anrb.ru
				                					                																			                												                	Rússia, 							Ufa						
S. Borisevich
Laboratory of Bioorganic Chemistry and Catalysis, Ufa Institute of Chemistry, Russian Academy of Sciences
														Email: newpharm@anrb.ru
				                					                																			                												                	Rússia, 							Ufa						
A. Kovalskaya
Laboratory of Bioorganic Chemistry and Catalysis, Ufa Institute of Chemistry, Russian Academy of Sciences
														Email: newpharm@anrb.ru
				                					                																			                												                	Rússia, 							Ufa						
P. Petrova
Laboratory of Bioorganic Chemistry and Catalysis, Ufa Institute of Chemistry, Russian Academy of Sciences
														Email: newpharm@anrb.ru
				                					                																			                												                	Rússia, 							Ufa						
C Khursan
Laboratory of Bioorganic Chemistry and Catalysis, Ufa Institute of Chemistry, Russian Academy of Sciences
														Email: newpharm@anrb.ru
				                					                																			                												                	Rússia, 							Ufa						
F. Zarudii
Laboratory of Bioorganic Chemistry and Catalysis, Ufa Institute of Chemistry, Russian Academy of Sciences; Department of Pharmacology No. 1, Bashkir State Medical University, Ministry of Health of the Russian Federation
														Email: newpharm@anrb.ru
				                					                																			                												                	Rússia, 							Ufa; Ufa						
Arquivos suplementares
 
				
			 
						 
						 
						 
						 
					 
				 
  
  
  
  
  Enviar artigo por via de e-mail
			Enviar artigo por via de e-mail  Acesso aberto
		                                Acesso aberto Acesso está concedido
						Acesso está concedido Somente assinantes
		                                		                                        Somente assinantes
		                                					